市場調査レポート
商品コード
1422996

子宮内膜症市場:タイプ別、診断・治療別、エンドユーザー別、地域別、2024年~2032年

Endometriosis Market by Type, Diagnosis and Treatment, End Users, and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 141 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
子宮内膜症市場:タイプ別、診断・治療別、エンドユーザー別、地域別、2024年~2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の子宮内膜症市場規模は2023年に24億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて4.71%の成長率(CAGR)を示し、2032年までに37億米ドルに達すると予測しています。世界市場は、症状や診断に関する意識の高まり、さまざまなジェネリック医薬品の普及、革新的な治療アプローチの開発、臨床試験の増加などを背景に、着実な成長を遂げています。

子宮内膜症市場の分析:

市場の成長と規模子宮内膜症の有病率の増加、認知度の向上、ヘルスケアインフラの進歩などを背景に、世界市場は力強い成長を遂げています。子宮内膜症の診断と治療を求める人が増え、革新的な治療ソリューションと包括的なヘルスケアサービスに対する需要が高まるにつれて、市場規模は拡大を続けています。

主な市場促進要因:主な促進要因としては、女性の健康問題に対する意識の高まり、診断能力の向上、研究開発活動の活発化などが挙げられます。さらに、患者中心のケアへの注力と新規治療オプションの導入も市場成長に大きく寄与しています。

技術の進歩:高度な画像診断技術、低侵襲手術、分子診断などの技術的進歩は、治療の展望を形成する上で極めて重要な役割を果たしています。これらの技術革新は診断精度を高め、手術結果を改善し、個別化された治療アプローチへの道を開く。

産業用途:この市場には、医薬品、医療機器、ヘルスケア・サービスなど、幅広い産業用途が含まれます。製薬会社は医薬品を積極的に開発・商品化しており、医療機器メーカーは診断や外科手術に使用される革新的なツールや機器で貢献しています。

主な市場動向:主な動向としては、早期診断の重視、製薬企業と研究機関の協力関係の強化、遠隔医療と患者のケアの統合などが挙げられます。さらに、症状だけでなく感情的・心理的側面にも対処する、全人的で患者中心のアプローチへのシフトが目立ってきています。

地理的動向:地域別動向では、地域によって市場成長率が異なり、北米は先進的なヘルスケア・インフラを背景に市場シェアでリードしています。アジア太平洋地域は、子宮内膜症の有病率の上昇とヘルスケア意識の高まりにより、大幅な成長を遂げています。

競合情勢:競合情勢は、研究開発および戦略的提携を通じて市場の成長に積極的に貢献している主要企業によって特徴付けられます。市場力学には、既存製薬企業とイノベーションを前面に押し出す新興企業とのバランスが含まれます。

課題と機会:課題には、診断の遅れ、特定の地域におけるヘルスケアへのアクセス制限、より効果的な長期管理オプションの必要性などが含まれます。機会は、研究の進展、世界な協力体制の強化、市場のアンメットニーズに対応する画期的な治療法の可能性などにあります。

将来の展望市場の将来は有望で、持続的な成長が見込まれます。継続的な研究、技術革新、患者中心のケアへの注力により、より効果的な治療法の開発が推進され、子宮内膜症の管理全体がさらに強化されることが期待されます。子宮内膜症に対する認識が高まり続ける中、市場は成長する態勢が整っており、既存のプレーヤーと新興プレーヤーの双方に成長機会がもたらされます。

子宮内膜症市場の動向:

認知度と診断率の向上

子宮内膜症市場の成長を促す主な要因の1つは、認知度の向上と診断率の改善です。子宮内膜症は、子宮の内膜に似た組織が子宮の外で増殖する病気です。この意識の高まりにより、より多くの女性が症状を認識し報告するようになり、早期の診断と介入が促されるようになった。さらに、ヘルスケアの専門家も子宮内膜症に関する知識を深めており、より正確でタイムリーな診断につながっています。その結果、効果的な治療法や管理オプションに対する需要が高まり、市場の成長を牽引しています。

医療研究と技術の進歩

医学研究と技術の継続的な進歩は、子宮内膜症治療の選択肢を形作る上で重要な役割を果たしています。新薬、低侵襲手術手技、個別化治療計画などの革新的治療アプローチの開発により、患者の利用可能な選択肢は大幅に拡大しました。高度な画像診断技術やバイオマーカー同定などの最先端の診断ツールは、より正確で効率的な診断に貢献しています。これらの進歩は、患者の予後を改善するだけでなく、この医学的疾患に対する新規でより効果的な治療法の強固なパイプラインを構築することにより、市場の成長を促進します。

女性のヘルスケア支出の増加と利用しやすさ

世界的に女性の健康が重視され、女性の医療支出が増加していることが、市場の拡大に寄与しています。社会が女性の健康問題に取り組むことの重要性を認識するにつれ、子宮内膜症に関連する研究、開発、質の高いヘルスケアサービスへのアクセスにリソースを割く意欲が高まっています。さらに、特に発展途上地域では、ヘルスケア施設へのアクセスが改善されたことにより、より多くの女性がこの疾患の診療を受け、適切な治療を受けることができるようになった。このような医療支出の増加とアクセスの向上が組み合わさることで、子宮内膜症分野の研究と患者ケアの両方により協力的な環境が醸成され、市場の成長が促進されます。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 子宮内膜症の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:タイプ別

  • 表在性腹膜病変
    • 市場動向
    • 市場予測
  • 子宮内膜腫
    • 市場動向
    • 市場予測
  • 深部子宮内膜症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳:診断・治療別

  • 診断
    • 市場動向
    • 主要セグメント
      • 超音波検査
      • 骨盤内検査
      • 腹腔鏡検査
      • 磁気共鳴画像法(MRI)
      • 子宮鏡検査
      • ソノヒステログラフィー
    • 市場予測
  • 治療
    • 市場動向
    • 主要セグメント
      • ホルモン療法
      • 疼痛管理
      • 保存的手術
    • 市場予測

第8章 市場内訳:エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 在宅ケア
    • 市場動向
    • 市場予測
  • スペシャリティセンター
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Abbvie Inc.
    • Bayer AG
    • Debiopharm Group
    • Gedeon Richter Plc
    • Kissei Pharmaceutical Co. Ltd.
    • Myovant Sciences GmbH
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Endometriosis Market: Major Drivers and Challenges
  • Figure 2: Global: Endometriosis Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Endometriosis Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Endometriosis Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Endometriosis Market: Breakup by Diagnosis & Treatment (in %), 2023
  • Figure 6: Global: Endometriosis Market: Breakup by End Users (in %), 2023
  • Figure 7: Global: Endometriosis Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Endometriosis (Superficial Peritoneal Lesion) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Endometriosis (Superficial Peritoneal Lesion) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Endometriosis (Endometrioma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Endometriosis (Endometrioma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Endometriosis (Deeply Infiltrating Endometriosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Endometriosis (Deeply Infiltrating Endometriosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Endometriosis (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Endometriosis (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Endometriosis (Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Endometriosis (Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Endometriosis (Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Endometriosis (Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Endometriosis (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Endometriosis (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Endometriosis (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Endometriosis (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Endometriosis (Speciality Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Endometriosis (Speciality Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Endometriosis (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Endometriosis (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Endometriosis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Endometriosis Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Endometriosis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Endometriosis Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Endometriosis Industry: Value Chain Analysis
  • Figure 79: Global: Endometriosis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Endometriosis Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Endometriosis Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Endometriosis Market Forecast: Breakup by Diagnosis & Treatment (in Million US$), 2024-2032
  • Table 4: Global: Endometriosis Market Forecast: Breakup by End Users (in Million US$), 2024-2032
  • Table 5: Global: Endometriosis Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Endometriosis Market: Competitive Structure
  • Table 7: Global: Endometriosis Market: Key Players
目次
Product Code: SR112024A6676

Abstract

The global endometriosis market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.71% during 2024-2032. The global market is experiencing steady growth driven by the rising awareness about symptoms and diagnosis, the widespread availability of various generic drugs, the development of innovative therapeutic approaches, and the increasing number of clinical trials.

Endometriosis Market Analysis:

Market Growth and Size: The global market is experiencing robust growth, driven by an increasing prevalence of the condition, rising awareness, and advancements in healthcare infrastructure. The market size continues to expand as more individuals seek diagnosis and treatment for endometriosis, fostering a demand for innovative therapeutic solutions and comprehensive healthcare services.

Major Market Drivers: Key drivers include the growing awareness of women's health issues, improved diagnostic capabilities, and a rise in research and development activities. Additionally, the focus on patient-centric care and the introduction of novel treatment options contribute significantly to the market growth.

Technological Advancements: Technological advancements, such as advanced imaging techniques, minimally invasive surgical procedures, and molecular diagnostics, play a pivotal role in shaping the landscape of treatment. These innovations enhance diagnostic accuracy, improve surgical outcomes, and pave the way for personalized treatment approaches.

Industry Applications: The market encompasses a wide range of industry applications, including pharmaceuticals, medical devices, and healthcare services. Pharmaceutical companies are actively developing and commercializing medications, while medical device manufacturers contribute with innovative tools and equipment used in diagnostic and surgical procedures.

Key Market Trends: Key trends include the emphasis on early diagnosis, increasing collaborations between pharmaceutical companies and research institutions, and the integration of telemedicine in patient care. Additionally, a shift towards holistic and patient-centered approaches, addressing not only symptoms but also the emotional and psychological aspects of the condition, is gaining prominence.

Geographical Trends: Geographical trends reveal varying rates of market growth across regions, with North America leading in terms of market share due to advanced healthcare infrastructure. The Asia Pacific region is witnessing substantial growth, driven by a rising prevalence of endometriosis and increasing healthcare awareness.

Competitive Landscape: The competitive landscape is characterized by key players actively contributing to the market's growth through research, development, and strategic partnerships. The market dynamics include a balance between established pharmaceutical companies and emerging players bringing innovation to the forefront.

Challenges and Opportunities: Challenges encompass issues related to delayed diagnosis, limited accessibility to healthcare in certain regions, and the need for more effective long-term management options. Opportunities lie in advancements in research, increased global collaboration, and the potential for breakthrough therapies addressing unmet needs in the market.

Future Outlook: The future of the market appears promising, with sustained growth anticipated. Continued research, technological innovations, and a focus on patient-centered care are expected to drive the development of more effective treatments, further enhancing the overall management of endometriosis. As awareness continues to grow, the market is poised for growth, presenting opportunities for both established and emerging players.

Endometriosis Market Trends:

Increased awareness and diagnosis rates

One of the primary factors fueling the growth of the market is the heightened awareness and improved diagnosis rates. In recent years, there has been a significant increase in public awareness regarding endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus. This heightened awareness has led to more women recognizing and reporting symptoms, prompting early diagnosis and intervention. Additionally, healthcare professionals are increasingly knowledgeable about the condition, leading to more accurate and timely diagnoses. As a result, the demand for effective treatments and management options has risen, driving growth in the market.

Advancements in medical research and technology

Ongoing advancements in medical research and technology have played a crucial role in shaping the landscape of endometriosis treatment options. The development of innovative therapeutic approaches, including new medications, minimally invasive surgical techniques, and personalized treatment plans, has significantly expanded the available choices for patients. Cutting-edge diagnostic tools, such as advanced imaging techniques and biomarker identification, contribute to more precise and efficient diagnosis. These advancements not only enhance patient outcomes but also drive market growth by creating a robust pipeline of novel and more effective therapies for this medical disorder.

Increasing female healthcare spending and accessibility

The growing emphasis on women's health and increased healthcare spending among the female population globally has contributed to the expansion of the market. As societies recognize the importance of addressing women's health issues, there is a greater willingness to allocate resources for research, development, and access to quality healthcare services related to endometriosis. Moreover, improved accessibility to healthcare facilities, especially in developing regions, ensures that a larger proportion of women can seek medical attention and receive appropriate treatment for this medical disorder. This combination of increased healthcare spending and enhanced accessibility propels market growth by fostering a more supportive environment for both research and patient care in the field of endometriosis.

Endometriosis Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, diagnosis and treatment, and end users.

Breakup by Type:

Superficial Peritoneal Lesion

Endometrioma

Deeply Infiltrating Endometriosis

Others

The report has provided a detailed breakup and analysis of the market based on the type. This includes superficial peritoneal lesion, endometrioma, deeply infiltrating endometriosis, and others.

Superficial peritoneal lesions are a common type of this disorder, characterized by the presence of endometrial-like tissue on the peritoneum-the thin membrane lining the abdominal cavity. These lesions often cause inflammation, scarring, and pain. Despite being superficial, they can significantly impact a patient's quality of life. Treatment approaches for superficial peritoneal lesions may include pain management, hormonal therapies, or surgical interventions to remove or ablate the lesions.

On the other hand, endometriomas, also known as ovarian cysts or chocolate cysts, occur when endometriotic tissue forms a cyst on the ovaries. These cysts can vary in size and may lead to pelvic pain, infertility, or complications during menstruation. Management of endometriomas often involves a combination of medical and surgical interventions. Surgical options may include cystectomy to remove the cyst while preserving ovarian tissue or oophorectomy in more severe cases. Hormonal treatments are also commonly employed to manage symptoms and prevent recurrence.

Furthermore, deeply infiltrating endometriosis involves the penetration of endometrial-like tissue into the deeper layers of organs within the pelvic cavity, such as the bowel, bladder, or uterosacral ligaments. This form can cause severe pain, organ dysfunction, and fertility issues. Management of deeply infiltrating endometriosis often requires specialized surgical procedures, such as excision surgery, to remove the deeply embedded tissue. Multidisciplinary care, involving gynecologists and other specialists, is crucial for comprehensive management. Hormonal therapies may also be employed to control symptoms and prevent recurrence in cases of deeply infiltrating endometriosis.

Breakup by Diagnosis and Treatment:

Diagnosis

Ultrasound

Pelvic Exam

Laparoscopy

Magnetic Resonance Imaging (MRI)

Hysteroscopy

Sonohysterography

Treatment

Hormonal Therapy

Pain Management

Conservative Surgery

A detailed breakup and analysis of the market based on the diagnosis and treatment have also been provided in the report. This includes diagnosis (ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography) and treatment (hormonal therapy, pain management, and conservative surgery).

The diagnosis involves a multi-faceted approach, combining clinical evaluation, imaging studies, and, in some cases, surgical procedures. Clinicians rely on a detailed medical history, including the description of symptoms such as pelvic pain, dysmenorrhea, and infertility. Physical examinations, including pelvic exams, may provide additional insights. Imaging techniques, such as transvaginal ultrasound or magnetic resonance imaging (MRI), aid in visualizing endometrial lesions and assessing their extent. Definitive diagnosis often requires laparoscopic surgery, allowing direct visualization and biopsy of endometriotic tissue.

On the other hand, the management of this disorder is tailored to individual patient needs and may involve a combination of medical, surgical, and supportive interventions. Hormonal therapies, including birth control pills, progestins, or GnRH agonists, are commonly employed to control symptoms by suppressing estrogen production. Non-steroidal anti-inflammatory drugs (NSAIDs) may be used for pain relief. In cases where fertility is a concern, assisted reproductive technologies (ART) or fertility-preserving surgeries may be considered. Surgical interventions, such as laparoscopic excision or ablation of endometrial lesions, aim to alleviate symptoms and improve fertility. In severe cases, particularly with deeply infiltrating endometriosis, more extensive surgeries may be necessary, involving excision of affected organs or tissues. Multidisciplinary care, involving gynecologists, fertility specialists, and pain management experts, is crucial for comprehensive treatment.

Breakup by End Users:

Hospitals

Homecare

Speciality Centers

Others

Hospitals represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end users. This includes hospitals, homecare, speciality centers, and others According to the report, hospitals represented the largest segment.

Hospitals serve as critical end-users in the market, playing a central role in diagnosis, treatment, and management of the condition. These institutions provide comprehensive care, including surgical interventions, medication administration, and post-operative monitoring. The collaborative nature of hospital settings facilitates the coordination of multidisciplinary teams, comprising gynecologists, surgeons, and other specialists, ensuring a holistic approach to the medical disi care. Moreover, hospitals often serve as hubs for medical research and innovation, actively contributing to the development of advanced treatment modalities and enhancing the overall landscape of this disorder management.

On the contrary, homecare represents an increasingly important segment in patient care, offering personalized and convenient solutions for individuals managing the chronic nature of the condition. Home-based care involves the administration of medications, pain management strategies, and monitoring of symptoms in the familiar and comfortable environment of patients' homes. This segment has witnessed growth with the advent of telemedicine, allowing healthcare professionals to remotely engage with patients, provide consultations, and monitor treatment adherence. Homecare not only enhances patient comfort but also contributes to cost-effective and efficient healthcare delivery, aligning with the trend toward patient-centric care models in the market.

Moreover, specialty centers dedicated to women's health and gynecological care have emerged as specialized end-users in the market. These centers focus on delivering targeted and specialized services for disorder diagnosis, treatment, and support. With a dedicated focus on gynecological conditions, these centers often house experts in the field, ensuring a high level of expertise and personalized care for patients with endometriosis. The establishment of these centers contributes to streamlined and efficient care pathways, fostering an environment that prioritizes the unique needs of individuals affected by endometriosis. Additionally, specialty centers frequently serve as hubs for clinical trials and research, driving advancements in the understanding and management of this medical disorder.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest endometriosis market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has consistently held a prominent position as the largest market, driven by factors such as advanced healthcare infrastructure, high awareness levels, and a significant focus on women's health. The region benefits from robust research and development activities, leading to the continuous introduction of innovative treatment options. Additionally, increasing awareness campaigns and advocacy efforts contribute to early detection and treatment. The prevalence of endometriosis cases and a well-established healthcare system with access to cutting-edge technologies further solidify North America's dominance in the global market.

The Asia Pacific region is witnessing substantial growth in the market, propelled by a rising prevalence of the condition, improving healthcare infrastructure, and increased awareness. As societies in the region become more attuned to women's health issues, there is a growing emphasis on early diagnosis and effective management of endometriosis. Pharmaceutical companies are expanding their presence in the Asia Pacific, introducing novel therapies and leveraging partnerships to address the changing healthcare needs of the population. Moreover, cultural shifts and changing demographics contribute to a greater focus on women's health in the region, fostering a conducive environment for market expansion.

Europe stands as a significant market, characterized by a high prevalence of the condition and a well-established healthcare system. The region benefits from extensive research initiatives, leading to the development of advanced treatment options. European countries prioritize women's health, and initiatives for early detection and management of endometriosis contribute to market growth. Collaboration between pharmaceutical companies and research institutions enhances the region's capabilities in driving innovations. The European market for endometriosis is characterized by a comprehensive approach to patient care, with a focus on both medical interventions and supportive services.

Latin America is experiencing a growing awareness of the disorder, leading to an expanding market for treatment options. The region grapples with challenges such as limited access to healthcare in certain areas, but initiatives aimed at improving healthcare infrastructure contribute to addressing these issues. Rising advocacy for women's health and increasing efforts to reduce the diagnostic and treatment gap are driving market growth in Latin America. Pharmaceutical companies are exploring opportunities in this region, introducing therapies and collaborating with local healthcare providers to enhance accessibility to endometriosis care.

The Middle East and Africa are emerging markets, marked by a gradual increase in awareness and healthcare infrastructure development. While the prevalence of this disorder is gaining recognition, the region faces challenges related to societal stigmas and limited healthcare resources in certain areas. However, ongoing efforts to address women's health issues and improve healthcare accessibility contribute to the market's growth. Pharmaceutical companies are increasingly exploring partnerships and market entry strategies to tap into the potential of this region, aiming to provide effective solutions for individuals affected by this disorder.

Leading Key Players in the Endometriosis Industry:

The key players in the market are driving growth through strategic initiatives, research and development, and market expansion. Pharmaceutical companies invest heavily in developing and commercializing innovative therapies for endometriosis. These companies leverage their expertise to create advanced medications that address the specific needs of patients, improving treatment outcomes. Collaborations and partnerships with research institutions further enhance their capabilities in understanding the disease and developing breakthrough solutions. Additionally, key players focus on expanding their market presence through geographical expansion and acquisitions. By entering emerging markets and acquiring smaller companies with promising pipelines, these players secure a competitive edge. Furthermore, they engage in educational initiatives and awareness campaigns, aiming to increase understanding of endometriosis among healthcare professionals and the general public, ultimately driving demand for their products and contributing to the overall growth of the market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

AbbVie Inc.

Bayer AG

Debiopharm Group

Gedeon Richter Plc

Kissei Pharmaceutical Co. Ltd.

Myovant Sciences GmbH

Sanofi S.A.

Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

January 8, 2024: Abbott and Tandem Diabetes Care, Inc. have jointly revealed the t:slim X2 insulin pump, equipped with Control-IQ technology has become the inaugural automated insulin delivery (AID) system to seamlessly integrate with Abbott's recently launched FreeStyle Libre 2 Plus sensor. This sensor represents Abbott's latest advancement in continuous glucose monitoring (CGM) technology, marking a collaborative effort to enhance the capabilities of insulin delivery systems and continuous glucose monitoring for individuals managing diabetes.

January 9, 2024: AbbVie introduced PRODUODOPA (foslevodopa/foscarbidopa) in the European Union. This medication is designed to address advanced Parkinson's disease accompanied by severe motor fluctuations, hyperkinesia (excessive movement), or dyskinesia (involuntary movement). PRODUODOPA is specifically intended for situations where combinations of existing Parkinson's medicinal products have not yielded satisfactory results.

January 8, 2024: Bayer announced the expansion of the clinical development program for the investigational compound elinzanetant.

Key Questions Answered in This Report:

  • How has the global endometriosis market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global endometriosis market?
  • What is the impact of each driver, restraint, and opportunity on the global endometriosis market?
  • What are the key regional markets?
  • Which countries represent the most attractive endometriosis market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the endometriosis market?
  • What is the breakup of the market based on the diagnosis and treatment?
  • Which is the most attractive diagnosis and treatment in the endometriosis market?
  • What is the breakup of the market based on the end users?
  • Which is the most attractive end users in the endometriosis market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global endometriosis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Endometriosis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Superficial Peritoneal Lesion
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Endometrioma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Deeply Infiltrating Endometriosis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Ultrasound
      • 7.1.2.2 Pelvic Exam
      • 7.1.2.3 Laparoscopy
      • 7.1.2.4 Magnetic Resonance Imaging (MRI)
      • 7.1.2.5 Hysteroscopy
      • 7.1.2.6 Sonohysterography
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Hormonal Therapy
      • 7.2.2.2 Pain Management
      • 7.2.2.3 Conservative Surgery
    • 7.2.3 Market Forecast

8 Market Breakup by End Users

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Speciality Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Debiopharm Group
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Gedeon Richter Plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Kissei Pharmaceutical Co. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Myovant Sciences GmbH
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Sanofi S.A.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Teva Pharmaceutical Industries Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report